Cardiovascular drugs. I: Antidysrhythmic drugs.
Wettrell
G
G
Andersson
K E
KE
D000404:Ajmaline / Q000494:pharmacology; D000638:Amiodarone / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000145:classification / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004206:Disopyramide / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000031:analogs & derivatives / Q000494:pharmacology; D008801:Mexiletine / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D016677:Tocainide; D014700:Verapamil / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D002317:Cardiovascular Agents; D000404:Ajmaline; D008801:Mexiletine; D016677:Tocainide; D010672:Phenytoin; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011342:Procainamide; D000638:Amiodarone